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Abstract
Background: In dystrophin-deficient muscles of Duchenne Muscular Dystrophy (DMD) patients and the mdx
mouse model, nitric oxide (NO) signalling is impaired. Previous studies have shown that NO-donating drugs
are beneficial in dystrophic mouse models. Recently, a long-term treatment (9 months) of mdx mice with
naproxcinod, an NO-donating naproxen, has shown a significant improvement of the dystrophic phenotype with
beneficial effects present throughout the disease progression. It remains however to be clearly dissected out
which specific effects are due to the NO component compared with the anti-inflammatory activity associated
with naproxen. Understanding the contribution of NO vs the anti-inflammatory effect is important, in view of the
potential therapeutic perspective, and this is the final aim of this study.
Methods: Five-week-old mdx mice received either naproxcinod (30 mg/kg) or the equimolar dose of naproxen
(20 mg/kg) in the diet for 6 months. Control mdx mice were used as reference. Treatments (or vehicle for control
groups) were administered daily in the diet. For the first 3 months the study was performed in sedentary animals,
then all mice were subjected to exercise until the sixth month. Skeletal muscle force was assessed by measuring
whole body tension in sedentary animals as well as in exercised mice and resistance to fatigue was measured
after 3 months of running exercise. At the end of 6 months of treatment, animals were sacrificed for histological
analysis and measurement of naproxen levels in blood and skeletal muscle.
Results: Naproxcinod significantly ameliorated skeletal muscle force and resistance to fatigue in sedentary as well
as in exercised mice, reduced inflammatory infiltrates and fibrosis deposition in both cardiac and diaphragm
muscles. Conversely, the equimolar dose of naproxen showed no effects on fibrosis and improved muscle
function only in sedentary mice, while the beneficial effects in exercised mice were lost demonstrating a limited
and short-term effect.
Conclusion: In conclusion, this study shows that NO donation may have an important role, in addition to
anti-inflammatory activity, in slowing down the progression of the disease in the mdx mouse model therefore
positioning naproxcinod as a promising candidate for treatment of DMD.
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Background
Duchenne Muscular Dystrophy (DMD) is the most com-
mon form of muscular dystrophy, affecting approxi-
mately one in every 3,500 live male births. It is caused
by mutations in the dystrophin gene [1]. DMD patients
exhibit progressive skeletal muscle degeneration and
weakness as well as cardiomyopathy [2]. Dystrophin-
deficient muscle exhibits chronic inflammation, and over
time, muscle fibres are steadily replaced with fibrotic
and fatty tissue [3]. Effective treatment for DMD is lack-
ing, resulting in premature death often before the age of
30 due to respiratory muscle weakness and/or cardiomy-
opathy [4]. Currently, corticosteroids constitute the pri-
mary treatment option for muscle dysfunction in DMD.
However, despite the extension of ambulation by 2–3
years and mitigation of pulmonary complications, the
use of steroids is associated with serious side effects [4].
Dystrophin deficiency in muscles results in the loss of
a large transmembrane protein complex, the dystrophin-
glycoprotein complex (DGC), which plays a structural
role in maintaining sarcolemmal integrity [5]. Among
the DGC proteins is the muscle-specific splice variant of
neuronal nitric oxide synthase μ (nNOSμ), which cataly-
ses the synthesis of nitric oxide (NO) in the skeletal
muscle. Therefore, the loss of dystrophin causes a sec-
ondary deficiency of nNOSμ, which is demonstrated to
significantly contribute to the pathogenesis and progres-
sion of DMD [6, 7]. NO is an important regulatory sig-
nal for a large number of physiological effects in the
muscle that are fundamental for muscle integrity and
function [8]. The mislocalisation and reduction of nNOS
expression and consequent reduction in NO generation
have been associated with impaired skeletal muscle con-
traction, vascular dilation, and eventual muscle damage
[9], as well as impaired muscle regeneration [10, 11]. It
has been shown that NO supplementation improves
blood flow and oxygen supply to contracting muscle,
thus reducing muscle ischemia and increasing glucose
uptake, muscle contraction and resistance to fatigue
[12, 13]. NO has also been documented to mediate activa-
tion of satellite precursor cells, providing new donor cells
for skeletal muscle growth and muscle repair from injury
or disease [10, 11]. Thus, increasing NO in muscle can
promote regeneration of dystrophic muscles.
A variety of pharmacological and genetic approaches
aimed at regulating NO supply to the muscle have been
shown to slow disease progression in several animal
models of skeletal muscular dystrophies, i.e. the mdx
and α-sarcoglycan null mice. Specifically, overexpression
of nNOS or treatment with NO donors such as molsido-
mine and isosorbide dinitrate (ISDN) attenuate skeletal
muscle inflammation and necrosis and/or improve exer-
cise performance in different mouse models of muscular
dystrophy [14–19].
A new class of NO-donating drugs called cyclooxy-
genase (COX)-inhibiting NO donors (CINODs) has
shown beneficial effects in preclinical models of mus-
cular dystrophies. This class of molecules combines a
classic COX inhibitor with a NO-donating moiety to
produce a dual pharmacological action [20]. Chronic
treatment (6–12 months) of mdx and α-sarcoglycan
null mice with the CINOD HCT 1026, an NO-donating
flurbiprofen, has been shown to markedly improve
muscle morphology and reduce muscle necrosis, in-
flammation, and fatigue [21]. Similar effects have been
observed in α-sarcoglycan null mice treated with NCX
320, an NO-donating ibuprofen [22]. HCT 1026 also
reverses functional muscle ischemia in mdx mice, an
effect which is maintained following prolonged treat-
ment, negating the concern that tolerance to the drug
might develop with chronic use [12]. This is a potential
drawback for some commonly-used NO donors such as
the organic nitrates (e.g., nitroglycerin and ISDN), since
their vasodilating properties decline following continu-
ous exposure [23]. Nitrate tolerance has also been re-
ported in the regulation of skeletal muscle blood flow
[24], also suggesting a potential limitation of this class
of compounds for chronic treatment of muscle disorders.
Another important side effect associated with organic ni-
trates is rapid hypotension due to the fast release of a large
amount of NO [25]. This effect has not been reported with
CINODs since they release NO at low concentrations for
prolonged periods [20]. Therefore, this new class of drugs
is effective at improving the dystrophic phenotype without
the limitations of nitrate tolerance and hypotension associ-
ated with the commonly-used organic nitrates.
Recently, the most advanced compound belonging to
the CINOD class, naproxcinod, a NO-releasing na-
proxen, has been demonstrated to improve the skeletal
and cardiac disease phenotype in mdx model of muscu-
lar dystrophy after long-term treatment. In that study,
in which a wild-type group was used in order to estab-
lish the recovery score obtained with the drug, treated
animals showed improved skeletal muscle and cardiac
function, reduced muscle inflammation and cardiac fi-
brosis and improved skeletal muscle blood flow [26].
Naproxcinod, has been widely investigated in animal
and clinical studies, including Phase III clinical trials
for osteoarthritis in more than 2,700 adult patients; the
safety database includes more than 4,000 patients [27].
Therefore, naproxcinod has been considered the ideal
candidate among CINODs to be developed for the
treatment of DMD.
Although naproxcinod has been shown to be effective
in the mdx mouse model of DMD, it is unclear to what
extent the NO properties contribute to its effects beyond
those related to naproxen-dependent anti-inflammatory
activity. Therefore, this study was designed to evaluate
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the NO-related activity of naproxcinod by comparison
with the anti-inflammatory naproxen in the mdx mouse
model following 6 months of treatment and evaluating
specifically the extent of benefit [28] as valid parameter
of drug efficacy.
Methods
Mice and treatment
Male mdx (C57BL/10-mdx) mice, 5 weeks of age, were
obtained from Jackson Laboratories (Bar Harbor, Maine)
and were handled according to Italian law for care and use
of laboratory animals (D.L. 26/2014), as well as European
Directive (2010/63/UE). The experimental procedures
used respected the standard operating procedures for pre-
clinical tests in mdx mice available on http://www.treat-
nmd.eu/research/preclinical/dmd-sops/.
A study by Uaesoontrachoon and coworkers [26] dem-
onstrated that 21 mg/kg/day of naproxcinod could be
considered an effective dose in mdx mice, while an
higher dose of 41 mg/kg/day lost beneficial activity.
Thus, a further study was designed to test an intermedi-
ate concentration of naproxcinod of 30 mg/kg/day in
term of efficacy in the DMD mouse model. In particular,
two doses of naproxcinod (10 and 30 mg/kg) were given
to mdx mice (n = 10 per group) for 7 months starting at
5 weeks of age. The compound was administered daily
in the diet (Mucedola, Milano, Italy), and the same diet
without drug was given to control mdx mice (n = 10).
Following 4 and 7 months of treatment, resistance to fa-
tigue was assessed by running treadmill assay. At the end
of treatment, morphological analysis of tibialis anterior
was performed.
Based on the results obtained in this exploratory study,
the dose of 30 mg/kg was identified as a further effective
dose of naproxcinod. According to this, five-week old
mdx mice (10 mice/group) were treated orally with ei-
ther naproxcinod (30 mg/kg), or an equimolar dose of
naproxen (20 mg/kg), starting at 1 month of age for
6 months. Control mdx mice were used as reference.
Treatments (or vehicle for control groups) were admin-
istered daily in the diet. Body weight and food intake
were monitored weekly for 5 months. For the first
3 months the study was performed in sedentary animals
and skeletal muscle force was assessed every month.
Then all mice were subjected to exercise for additional
3 months. Finally, resistance to fatigue and skeletal
muscle force were measured after 3 months of running
exercise (i.e. 6 months of treatment) to evaluate the ef-
fects of treatment on muscle function in exercised ani-
mals. Once completed the functional tests, animals were
sacrificed for histological analysis and measurement of
blood and skeletal muscle naproxen levels. Results are
reported as the extent of benefit between the treated
and untreated groups of mdx mice [28].
Treadmill to impact on mdx phenotype
In order to impact on mdx phenotype, in the second
study all mice, from the third month of treatment, were
subjected to a 30 min run on a horizontal treadmill
using the Exer 3/6 Treadmill (Columbus Instruments,
USA) at 10 m/min, twice a week as described in the
TREAT-NMD SOP DMD_M.2.1.001 [29]
Treadmill to assess dystrophic state
Resistance to fatigue was assessed by treadmill running to
exhaustion, using the Exer 3/6 Treadmill; (Columbus
Instruments, Columbus, OH) and modelling the six mi-
nute walk test currently recommended as the key outcome
measure in human trials for DMD. The exhaustion tread-
mill test was performed after an appropriate training
period and four tests were performed on the same animal,
allowing one week between each test.
In the first study, the exercise resistance test was per-
formed for four weeks (once a week) at an uphill inclin-
ation of 30 %, for 5 min at 1 m/min modifying protocols
already described in literature [17, 30, 31]. Then, the speed
was increased by 1 m/min every 2 min until exhaustion.
In the second study, the assay consisted of horizontal
running for 5 min at 5 m/min, and then the speed was
increased by 1 m/min each minute until exhaustion as
reported in the TREAT-NMD SOP (DMD M.2.1.003).
The test measured time of running and total distance
run by each mouse until exhaustion.
Skeletal muscle force: Whole body tension assay
In vivo skeletal muscle force was measured every month
for the first 3 months of treatment by whole body ten-
sion (WBT) in sedentary mdx mice, using Grass FT03
transducer and following the specific SOP (DMD
M.2.2.006). The WBT procedure is used to determine
the ability of mice to exert tension in a forward pulling
manoeuvre that is elicited by stroking the tail. It is
thought to reflect the maximal acute phasic force the
mouse can achieve to escape a potentially harmful event.
The total phasic (or acute) forward pulling tension
(FPT) exerted by the fore- and hind limb musculature of
mice were recorded and normalized by body weight. In
vivo muscle force was also measured at 6 months of
treatment following the 4 weeks of treadmill exhaustion
test, to assess the impact of exercise on muscle function.
The results were expressed as WBT5 and WBT10,
which are calculated as the top 5 and 10 FPTs, respect-
ively, divided by body weight.
Histology
At the end of treatment, muscle samples (from diaphragm
and tibialis anterior muscles) were frozen in liquid
nitrogen-cooled isopentane and serial 10 μm thick sec-
tions were cut with a Leica cryostat. Sections were then
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stained with haematoxilin and eosin (H&E) according to
the standard procedure. At least 3–4 random images for
each muscle were taken at 10x magnification with a DMI
4000B microscope (Leica Microscopy Systems, Heerbrugg,
Switzerland). Image acquisition was performed by Leica
LAS AF software version 2.5.0.6735 and analysed in a
blinded fashion using digitised imaging systems (Image J -
National Institute of Health) to evaluate infiltrated inflam-
matory areas.
In the second study, skeletal muscle fibrosis was also
measured by the Masson’s Trichrome staining for de-
tecting collagen inside the muscle, according to the
standard protocol [22]. The fibrotic area corresponding
to the area stained in blue was quantified and compared
to the total area of the tissue section through image ana-
lysis software (Image J - NIH).
In addition to skeletal muscles, in the second study,
heart and gastric samples were also removed, fixed in
10 % formalin and sectioned. Both stomach and heart
were sectioned and stained for H&E by Consorzio MIA
(Monza, Italy). Five random digital images of each gastric
sample were taken using an Eclipse E600 (Nikon, Japan)
microscope. Picro-Sirius red staining was performed to
measure the degree of cardiac fibrosis according to the
standard procedure [26]. Eight random Picro-Sirius
stained sections of each heart sample were digitalized
using the Aperio ScanScop XT System (Aperio Technolo-
gies; Vista, CA), and blinded analysis was done using
Image J (NIH), with additional threshold colour plug-ins
to process images. Pixels corresponding to the area stained
in red were normalised to the total pixel area of the tissue
image and the results expressed as percentage of fibrosis.
Naproxen blood level quantification
At the end of the second study, animals were sacrificed
and blood samples were taken by heart puncture. 50 μl of
each blood sample were protein-precipitated by adding
150 μl of acetonitrile (ACN) and 10 μl of dimethyl sulfox-
ide (DMSO) in triplicate, vortex-mixed and centrifuged
for 10 min at 4 °C (3200 g); the supernatant was trans-
ferred to a clean tube and kept at −80 °C until LC-MS/MS
analysis of naproxen.
The analytical system comprised a Sciex API 4000 mass
spectrometer (Apply Byosistem, Foster City, CA), a CTC
HTS PAL autosampler (LEAP Technologies, Carrboro,
NC), and Agilent LC-1200 pump (Agilent Technologies,
Santa Clara, CA). The samples were analyzed using
reverse-phase chromatography (Poroshell 120 EC-C18
2.1x50mm 2.7 μm; Agilent Technologies, Santa Clara, CA)
and the column temperature was maintained at 40 °C. A
1.7-min linear gradient from 70 to 0 % of mobile phase A
(formic acid 0.1 %) was used at the flow rate of 0.5 ml/min,
and mobile phase B was acetonitrile containing 0.1 % of
formic acid. Positive ion multiple reaction monitoring with
parent /fragment 231.15→ 185.05 was used to monitor na-
proxen levels in the experiment.
Naproxen skeletal muscle level quantification
At the end of treatment, animals were sacrificed and
gastrocnemius samples were removed, immediately fro-
zen in liquid nitrogen and stored at −80 °C until ana-
lyzed. Then, each sample was homogenized in a mortar
in the presence of liquid nitrogen and three volumes of
ACN were added. Thereafter, samples were vortex-
mixed and centrifuged for 10 min at 4 °C (3200 g). The
supernatant was transferred to a clean tube and analyzed
by LC-PDA for naproxen level quantification. Data were
reported as ng of naproxen in mg of tissue.
Liquid chromatography was performed on ACQUITY
UPLC system (Waters Corp., Milford, MA) with auto-
sampler and column oven enabling temperature control
of analytical column. AQUITY UPLC BEH C18 column
(2.1x50mm, 1.7 μm; Waters Corp., Milford, MA) was
employed. The column temperature was maintained at
40 °C. A 1.7-min linear gradient from 60 to 0 % of mo-
bile phase A (formic acid 0.1 %) was used at the flow
rate of 0.5 ml/min, and mobile phase B was methanol
containing 0.1 % of formic acid.
PDA detection was carried out on ACQUITY UPLC
PDA detector (Waters Corp., Milford, MA). Wavelength
of 230 nm was used to monitor naproxen levels in the
experiment.
Statistical analysis
Results were expressed as the means ± SEM. The differ-
ences between mean values were assessed by one-way
ANOVA, followed by the Tukey post-hoc test or by two-
way ANOVA followed by the Bonferroni post-hoc test
when appropriate. A P-value < 0.05 was considered statis-
tically significant.
Results
Naproxcinod at 30 mg/kg is effective in the mdx mouse
model of DMD
Two doses of naproxcinod (10 and 30 mg/kg) were tested
in the mdx mouse model to better assess drug efficacy and
range of activity. Mdx mice were treated for 7 months with
vehicle and a low or high dose of naproxcinod incorporated
into the diet starting at 5 weeks of age. The dose of 30 mg/
kg of naproxcinod showed a significant improvement (P <
0.05) in running distance until exhaustion compared to
vehicle-treated mdx mice, with the distance run 46 % and
49 % greater at 4 and 7 months respectively (Fig. 1a and b).
In addition, tibialis anterior muscles from mdx mice receiv-
ing 30 mg/kg naproxcinod for 7 months showed a signifi-
cantly smaller area of infiltrate ( −70 %, P < 0.05) than mdx
mice treated with vehicle (Fig. 1c and d). Conversely, the
lower dose of 10 mg/kg confirmed a slight effect on muscle
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function which did not reach statistical significance (Fig. 1a
and b), and no effects on muscle structure (Fig. 1c and d),
as already published [26]. Based on these results, the dose
of 30 mg/kg was identified as a further effective dose and
selected for the study in comparison with naproxen.
Naproxcinod- and naproxen-treated mice have similar
body weights and food intake
Mdx mice were given either naproxcinod (30 mg/kg) or an
equimolar dose of naproxen (20 mg/kg) incorporated into
the diet starting at 5 weeks of age. The same diet without
any drug was used as the control diet. All animals were
weighed every week for 5 months. There were no statisti-
cally significant differences in body weight between the ve-
hicle group and either treated group (Additional file 1a).
Food was weighed every week for 5 months and no sig-
nificant difference in food intake/mouse/day was de-
tected between the groups (Additional file 1b).
Naproxcinod improved skeletal muscle force in sedentary
mdx mice
In vivo skeletal muscle force was measured every month
for the first 3 months of treatment by whole body ten-
sion (WBT). Following the first month of treatment,
Fig. 1 30 mg/kg of naproxcinod is an effective dose in mdx mice. In a first exploratory study, mdx mice were treated with two doses of naproxcinod
(10 and 30 mg/kg) for 7 months. Locomotor function, assessed by treadmill running to exhaustion, was measured after 4 (a) and 7 months
(b) of treatment. Quantification of inflammation in the tibialis anterior muscle of mdx mice treated with vehicle, 10 or 30 mg/kg naproxcinod
was performed at the end of treatment. c Representative histological images of the tibialis anterior muscle after H&E staining and d quantification of
inflammatory infiltrate area. Data are presented as mean ± SEM. *represents the comparison between vehicle and all the treatment groups. One-way
ANOVA followed by Tukey post-hoc test. *P < 0.05. N = 8-10 mice/group. Bar = 100 μm
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both naproxen and naproxcinod significantly improved
skeletal muscle force as indicated by an increase in the
parameters WBT5 (55 % for naproxen, 80 % for naproxci-
nod, P < 0.01 vs vehicle) and WBT10 (51 % for naproxen,
76 % for naproxcinod, P < 0.01 vs vehicle; Additional file
2a and b). Interestingly, for WBT10, naproxcinod showed
a significantly greater improvement of muscle force com-
pared to naproxen (16 % greater, P < 0.05).
The significant beneficial effects of both drugs on skel-
etal muscle force assessed by WBT were maintained
with treatment over the following 2 months (WBT5:
44 % for naproxen, 46 % for naproxcinod, P < 0.001 vs
vehicle; WBT10: 48 % for naproxen, 56 % for naproxci-
nod, P < 0.001 vs vehicle, Additional file 2c and d) and
3 months (WBT5: 50 % for naproxen, 56 % for naproxci-
nod, P < 0.001 vs vehicle; WBT10: 55 % for naproxen,
63 % for naproxcinod, P < 0.001 vs vehicle; Additional
file 2e and f). However, there was no significant differ-
ence between the two drug treatments.
Naproxcinod increased resistance to fatigue in exercised
mdx mice compared to naproxen
Resistance to fatigue was assessed by the treadmill run-
ning assay at the 6-month time point following 3 months
of running exercise twice/week (30 min at 10 m/min
speed). Exercised vehicle-treated mdx mice showed a
dramatic increase in fatigability between the start and
the fourth week of running to exhaustion (P < 0.05;
Fig. 2a). Naproxen-treated mdx mice also showed a
trend of increased fatigability throughout the 4 weeks of
running. However, naproxcinod-treated mice showed the
same resistance to fatigue as at the start of the running
session (Fig. 2a). For running performance at the fourth
week, 30 mg/kg naproxcinod significantly improved
resistance to fatigue with a 46 % mean increase (P < 0.05)
in distance travelled compared to vehicle. In contrast, na-
proxen showed only a trend toward improvement of about
10 % (Fig. 2b). Moreover, naproxcinod resulted in better
protection against fatigue compared to naproxen (by
about 30 %), although this effect did not reach statistical
significance because of inter-animal variability.
Naproxcinod improved skeletal muscle force in exercised
mdx mice compared to naproxen
In vivo skeletal muscle force was assessed by WBT assay
at 6 months of treatment in exercised mdx mice, 24 h
after the 4 weeks of running to exhaustion. Naproxcinod
treatment led to a significant improvement of both
WBT5 and WBT10 (57 % and 53 % respectively, P <
0.001) compared to vehicle-treated mdx mice (Fig. 3a
and b). In addition, the WBT values at 6 months of
treatment in exercised mice were similar to those after 2
and 3 months of treatment in sedentary mdx mice, thus
suggesting that naproxcinod maintains its efficacy up to
6 months of treatment and protects against exercise-
induced skeletal muscle weakness. Conversely, naproxen,
which at 2 and 3 months of treatment in sedentary con-
ditions showed an effect in the WBT assay similar to
that of naproxcinod, did not maintain its efficacy when
tested at 6 months in trained mdx mice. In particular,
naproxen-treated mdx mice showed only 30 % improve-
ment for WBT5 (P < 0.05) and 25 % for WBT10 (NS)
compared to vehicle-treated mdx mice. Therefore, the
beneficial effects of naproxcinod on skeletal muscle force
were significantly greater (around 20 % for both WBT5
and WBT10, P < 0.05) than those of naproxen, thus sug-
gesting an important role for NO in counteracting
exercise-induced skeletal muscle weakness.
Fig. 2 Naproxcinod improves resistance to fatigue in exercised mdx mice. Resistance to fatigue was assessed by treadmill running to exhaustion
following 6 months of treatment in exercised mdx mice with either vehicle (black bar), 20 mg/kg naproxen (grey bar) or 30 mg/kg naproxcinod
(white bar). a Measurements made once a week for four consecutive weeks and b data obtained during the fourth week of running to exhaustion.
Data are presented as mean ± SEM. # represents the comparison between each time point. Two-way ANOVA followed by Bonferroni post-hoc test.
*represents the comparison between vehicle and all the treatment groups. One-way ANOVA followed by Tukey post-hoc test. * and # P < 0.05.
N = 8-10 mice/group
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Naproxcinod reduced diaphragm inflammation and
fibrosis in mdx mice
Histology of H&E-stained sections of the diaphragm
muscles was assessed for inflammation. Histology profile
of mdx diaphragm muscles shows typical dystrophic fea-
tures, such as the alteration of the muscle architecture
with areas of infiltrates and a large non-muscle area,
likely due to the deposition of fibrotic and adipose tissue
(Fig. 4a). A blinded morphometric analysis revealed a
significant reduction in inflammatory infiltrate when
mice were treated with naproxen ( −39 %, P < 0.001) and
naproxcinod (−50 %, P < 0.001), respectively (Fig. 4a and b).
Masson Trichrome staining for collagen revealed, as ex-
pected, fibrosis in the diaphragm sections of mdx mice.
Naproxen-treated mice showed the same level of fibrosis
observed in vehicle-treated mdx mice, while treatment with
naproxcinod significantly reduced diaphragm fibrosis de-
position compared to both vehicle ( −47 %, P < 0.01) and
naproxen ( −39 %, P < 0.05) (Fig. 5a and b).
Naproxcinod reduced cardiac fibrosis in mdx mice
Given the effects on fibrosis with naproxcinod in dia-
phragm samples, we also assessed the level of fibrosis in
the heart using Picro-Sirius red staining. Heart samples
from mdx mice showed fibrosis deposition as previously
reported [32, 26]. As in the diaphragm muscle, treatment
Fig. 3 Naproxcinod improves skeletal muscle force in exercised mdx
mice. a WBT5 and b WBT10 measured following 6 months of treatment
in exercised mdx mice treated with vehicle (black bar), 20 mg/kg
naproxen (grey bar), or 30 mg/kg naproxcinod (white bar). Data are
presented as mean ± SEM. *represents the comparison between vehicle
and treatment groups. # represents the comparison versus the
naproxen-treated group. One-way ANOVA followed by Tukey post-hoc
test. * and # P< 0.05, ***P< 0.001. N= 8-10 mice/group
Fig. 4 Naproxcinod significantly reduces inflammation in diaphragm of mdx mice. Quantification of inflammation in the diaphragm of mdx mice
treated with vehicle (black bar), 30 mg/kg naproxcinod (white bar) or 20 mg/kg naproxen (grey bar) following 6 months of treatment. a Representative
histological images of the diaphragm muscle after H&E staining and b quantification of the area of inflammatory infiltrates, expressed as a percentage
of muscle cross section. Data are presented as mean ± SEM. *represents the comparison between vehicle and treatment groups. One-way ANOVA
followed by Tukey post hoc test. ***P < 0.001. N = 4-5 mice/group. Bar = 100 μm
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with 30 mg/kg naproxcinod caused a significant reduction
in cardiac fibrosis compared to either vehicle or naproxen
treated mdx mice ( −35 %, P < 0.01 and - 29 %, P < 0.05,
respectively), while the equimolar dose of naproxen did
not show any significant effect (Fig. 6a and b).
Naproxcinod caused less gastric damage than naproxen
in mdx mice
Since non-steroidal anti-inflammatory drugs are known to
induce gastric mucosal damage following chronic treat-
ment, a blinded qualitative morphological analysis of the
stomach of these animals was performed. As expected, a
6-month treatment with 20 mg/kg naproxen altered the
gastric mucosa compared to vehicle-treated mdx mice,
markedly reducing the mucosal layer (especially foveolar
cells). In contrast, naproxcinod caused a clearly reduced
level of gastric damage (Additional file 3).
Naproxcinod showed reduced bioavailability compared to
naproxen
In order to verify if naproxcinod given at a dose equimo-
lar to naproxen was able to release the same amount of
naproxen following oral administration, we examined
the blood levels of drug of treated mice. Following
6 months of treatment with either naproxcinod (30 mg/kg)
or the equimolar dose of naproxen (20 mg/kg) incorpo-
rated into the diet, the blood levels at steady state of
naproxen were measured by LC-MS/MS. Blood levels
of naproxen were 12.4 ± 2.6 μM, while those in blood
samples of animals treated with naproxcinod were 4.1 ±
1.3 μM. These data underline a reduced bioavailability of
naproxcinod compared to naproxen of about 3-fold. Simi-
lar results were found in gastrocnemius muscle samples,
where animals treated with naproxcinod showed concen-
trations of 0.07 ± 0.01 ng/mg of tissue, while those treated
with naproxen showed 0.2 ± 0.1 ng/mg of tissue.
Discussion
Naproxcinod is the most advanced of a new class of
anti-inflammatory agents, CINODs, in which a stand-
ard COX-inhibiting NSAID such as naproxen is linked
to a NO-donating moiety to produce dual pharmaco-
logical actions [33, 20]. Naproxcinod, upon absorption, is
metabolized to naproxen and the NO–donating moiety,
which in turn releases NO through enzyme bioactivation.
This class of drugs was initially developed as therapeutic
alternatives to the NSAIDs for the treatment of osteoarth-
ritis (OA). The addition of the NO-donating moiety was
Fig. 5 Naproxcinod significantly reduces fibrosis in diaphragm of mdx mice. Quantification of fibrosis content assessed by Masson’s Trichrome
staining in the diaphragm of mdx mice treated with vehicle (black bar), 30 mg/kg naproxcinod (white bar), or 20 mg/kg naproxen (grey bar)
following 6 months of treatment. a Representative histological images of the diaphragm and b quantification of fibrotic area, expressed as a
percentage of muscle cross section. Data are presented as mean ± SEM. *represents the comparison between vehicle and treatment groups.
#represents the comparison versus the naproxen-treated group. One-way ANOVA followed by Tukey post-hoc test. ** P < 0.01; # P < 0.05. N = 4-5
mice/group. Bar = 100 μm
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aimed at reducing common adverse effects of chronic
NSAID use, such as gastrointestinal damage and increased
blood pressure. Indeed, naproxcinod was shown in several
clinical trials to be effective in relieving the signs and
symptoms of OA compared to placebo [27, 34–36], but
with a lower incidence of hypertension compared to
NSAIDs [37, 38]. Moreover, it has been demonstrated that
the effects of naproxcinod ascribed to NO such as the con-
trol of blood pressure (BP) persist over time [38] up to
13 weeks, suggesting that the compound does not lead to
development of nitrate tolerance with the chronic use.
However, FDA approval was not granted, as additional
long-term clinical studies were requested to differentiate
the drug from reference NSAIDs. Recent preclinical
studies suggest, however, that CINODs are effective in
muscular dystrophy models (21).
The beneficial effects of CINOD treatment in dystrophic
mice are related to a combination of effects ranging from
reduced inflammation and necrosis and preserved regen-
erative capacity of muscle to improved skeletal muscle
blood flow. A previous study with naproxcinod demon-
strated that it was effective at improving the dystrophic
phenotype in the mdx mouse model following long-term
treatment [26]. Specifically, naproxcinod improved skeletal
muscle and cardiac functions, and reduced skeletal muscle
inflammation as well as cardiac fibrosis following 9 months
of treatment. Importantly, these beneficial effects persisted
throughout disease progression, without adverse side
effects such as those observed with prednisolone, the
current treatment option for DMD. Therefore, the
compound was shown to be effective and better tolerated
than the therapy currently used for DMD. However, the
studies performed to date had not yet demonstrated the
specific contribution of the NO-donating moiety over the
COX-inhibiting activity. Therefore, in the present work,
naproxcinod was studied in comparison with its parent
drug naproxen, to investigate any additional effects of
NO-donation over and above COX-inhibition.
The dose of 30 mg/kg used in this study was selected in
order to optimize drug dosage, i.e. to identify the maximal
effective dose, higher than the one previously found effect-
ive, but below the 41 mg/kg, a dose at which naproxcinod
lost its efficacy in mdx mice [26]. Although no data are
available explaining the loss of efficacy observed with the
high dose of naproxcinod, the involvement of nitrosylation
in causing this effect is a possibility. S-nitrosylation of the
ryanodine receptor (RyR1) indeed contributes to promote
muscle weakness in mdx skeletal muscles by altering Ca2+
homeostasis [39], and S-nitrosylation of SIRT1 (silent mat-
ing type information regulation 2 homolog) results in the
induction of pro-inflammatory pathways [40]. However,
here we did not observe any muscle weakness. Interest-
ingly, it is not unusual to observe bell-shaped dose re-
sponse curves with drugs used for the treatment of DMD
condition (i.e. ataluren) [41]. This suggests that caution in
dose selection is particularly relevant in a such clinical set-
ting as DMD.
Based on the results obtained, the dose of 30 mg/kg
was fully effective at improving skeletal muscle function
and morphology. In addition, the dose chosen is in the
Fig. 6 Naproxcinod significantly reduces cardiac fibrosis. Quantification of the cardiac fibrosis assessed by Picro-Sirius staining in mdx mice treated
with vehicle (black bar), 30 mg/kg naproxcinod (white bar), or 20 mg/kg naproxen (grey bar) following 6 months of treatment. a Representative
images of the heart and b quantification of the area of fibrosis in the heart, expressed as a percentage of the whole heart. Data are presented as
mean ± SEM. *represents the comparison between vehicle and the treatment groups. #represents the comparison versus the naproxen-treated
group. One-way ANOVA followed by Tukey post-hoc test. **P < 0.01; # P < 0.05. N = 5-10 mice/group. Bar = 1 mm
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upper range of a clinically daily effective dose (i.e. 750 mg
bid which corresponds to 20–25 mg/kg/day). In contrast,
10 mg/kg did not induce any significant beneficial effects
on the parameters measured. Therefore, the dose of
30 mg/kg was used for the full study in comparison with
naproxen.
Treatment of mdx mice with naproxcinod (30 mg/kg)
for 6 months did not result in any effects on body
weight or food consumption compared to both control
and naproxen-treated animals, suggesting that the com-
pound was safe throughout the duration of treatment.
Naproxcinod treatment significantly improved skeletal
muscle force already after the first month of treatment
in sedentary animals; this effect was also maintained
throughout the duration of treatment even when mice
were forced to exercise. The equimolar dose of naproxen
(20 mg/kg) caused an improvement of muscle force that
was comparable to naproxcinod only at 2 and 3 months
of treatment in sedentary animals.
However, when animals were forced to run, a condition
in which muscle damage is enhanced [42–44], naproxen’s
effects on muscle force were significantly lower than those
of naproxcinod. Similar effects were also observed on
locomotor function. When exercised mice were forced to
run until exhaustion, only those treated with naproxcinod
showed a significantly improved resistance to fatigue com-
pared to control animals. These data on muscle function
could suggest that in sedentary adult mdx mice, inflamma-
tion is likely the main pathologic event, and therefore the
reduction of inflammation is sufficient to improve muscle
function. When the severity of the phenotype is increased
by forcing animals to exercise, achieving beneficial effects
by these drugs requires additional mechanisms beyond
anti-inflammatory action. Indeed, under such conditions,
the assumption is that NO, released by naproxcinod, could
become relevant over the anti-inflammatory action.
In particular, the pathophysiology of DMD also includes
the exhaustion of the myogenic pool of cells and necrosis
together with fibrosis and fat deposition, a condition in
which the role of NO has been shown to be important
[45, 11]. Indeed, NO is known to play an important role in
stimulating skeletal muscle regeneration, thus maintaining
functional muscle tissue for longer [10, 46]. The improve-
ment in resistance to fatigue may also be explained by the
ability of NO donors to alleviate muscle ischemia, a defect
associated with the loss of sarcolemmal nNOS in the dys-
trophic muscle fibres [12]. Sarcolemma-targeted nNOS at-
tenuates α-adrenergic vasoconstriction in contracting
muscles and improves muscle perfusion during exercise
[47]. This process is defective in both mdx mice and pa-
tients with DMD [48, 9], thus promoting fatigue and in-
jury of dystrophic muscles. Indeed, it has been recently
demonstrated that naproxcinod at both 20 and 40 mg/kg
is able to counteract skeletal muscle ischemia in mdx mice
following one week of treatment, an effect not observed
with naproxen [49]. Overall, these findings demonstrate
an additional mechanism of action of naproxcinod, medi-
ated by NO, which supports and explains the additional
beneficial effects of naproxcinod over COX-mediated anti-
inflammatory action.
However, it must also be added that the use of a mixed
protocol, on both sedentary and exercised mice, as we
did here, while providing valuable information may not
provide a straightforward interpretation of the results as
it would be with pure protocols based only on sedentary
or exercised groups of mice. Thus, we cannot excluded
other possible explanations of the results such as a dif-
ferent time-dependent effect of the two drugs, with
naproxcinod being more effective than naproxen over
chronic use.
Interestingly, naproxcinod showed an anti-inflammatory
activity comparable to that of naproxen, reducing dia-
phragm inflammatory infiltrates, despite a bioavailability
3-fold lower than that of naproxen. These data are in
agreement with previous pharmacokinetics studies where
plasma availability of naproxen following naproxcinod oral
administration was found to be lower (55 and 85 % in rats
and mini-pigs, respectively) than that observed after ad-
ministration of an equimolar dose of naproxen [50]. Simi-
larly, in healthy volunteers relative plasma bioavailability
of naproxen after naproxcinod administration was re-
ported as 80–85 % compared with the availability of an
equimolar dose of naproxen [51]. Despite these differences
in availability of naproxen, no negative effects were ob-
served on the efficacy of naproxcinod in reducing pain
and inflammation in the hip and knee of patients with
OA [34–36] in a way similar to that observed for the
anti-inflammatory effects in mdx mice.
The data are explained by the additional anti-
inflammatory properties associated with NO, which are
not mediated by COX inhibition, namely the inhibition
of both NF-kB activation and iNOS expression [52].
According to this, it has been shown that the precursor
of NO, L-arginine, down-regulates levels of NF-κB in
mdx muscles, resulting in lower activation of its down-
stream signaling and inhibition of two muscle-specific
metalloproteinases, MMP-2 and MMP-9 [53]. Further-
more, long-term treatment with NO significantly reduces
skeletal muscle inflammatory infiltrates and fibrosis by
modulating the innate inflammatory response, increasing
macrophage recruitment, and promoting a more efficient
clearance of cell debris [54]. Both mechanisms of NF-κB
inhibition and modulation of innate inflammatory re-
sponse contribute to explain why the anti-inflammatory
activity of naproxcinod is similar to that of naproxen in
spite of its lower bioavailability. A further important find-
ing, which may also explain the greater efficacy of naprox-
cinod on muscle function, is the reduction of fibrosis
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deposition in both diaphragm and heart. This effect could
be ascribed to NO, since naproxen had no effect on this
parameter. Consistent with this result, it has been recently
demonstrated that NO regulates fibro-fatty tissue depos-
ition in dystrophic skeletal muscle [45]. This effect may be
mediated by the NO-dependent regulation of both miR-
133a, a known regulator of collagen 1A1 expression [55],
and miR-27b, a key inhibitor of adipocyte differentiation
that controls the expression of peroxisome proliferator-
activated receptor γ [56].
As well as relieving skeletal muscle disease, an effect-
ive therapy of DMD must also improve cardiac function,
as heart failure is one of the key events leading to DMD
patient decline and death [4]. The progression of DMD
in cardiac muscle is much slower than in skeletal muscle
and is characterized by reduced systolic function and
cardiac arrhythmias [57, 58]. Unlike skeletal muscle, car-
diac muscle is incapable of regeneration, since it lacks
stem cells similar to the satellite cells of skeletal muscle
[59]. In the present study, naproxcinod-treated animals
showed a 35 % reduction in cardiac fibrosis compared
with mdx control mice. This reduction is consistent with
previous studies, where the inhibitory effects exerted by
naproxcinod on cardiac fibrosis were also associated with
a significant improvement of cardiac function [26], thus
confirming the potential beneficial effects of naproxcinod
treatment on DMD cardiomyopathy. In contrast, naproxen
did not reduce cardiac fibrosis, suggesting once more that
the effect on fibrosis can be ascribed to NO donation. In
support of this, Wehling-Henricks et al. [60] found that
overexpression of nNOS can effectively improve cardiomy-
opathy caused by dystrophin deficiency and that the im-
proved cardiac function is associated with reduced cardiac
fibrosis. Further evidence of the cardioprotective role of
nNOS-derived NO has been recently demonstrated by the
mitigation of heart pathology and improvement of heart
function by nNOS gene therapy in aged mdx mice [61].
An aspect that has to be considered carefully when
dealing with chronic therapies is the possibility of ad-
verse events leading to significant tissue damage. In the
case of NSAIDs a key issue is gastric damage [62]. Here,
as expected, marked naproxen-induced gastric damage
occurred after 6 months of treatment, while naproxcinod
had a milder effect on the gastric mucosa. The safer gas-
tric profile of naproxcinod could be explained by the
known protective effects of NO in the gastrointestinal
tract [63] but also by the reduced bioavailability of the
compound.
Conclusion
In conclusion, this study confirms the efficacy and the
safety profile of naproxcinod in the mdx mouse model
of DMD, and demonstrates a clear difference between
naproxcinod and its parent drug naproxen. Naproxcinod
has superior effects in improving muscle function and re-
ducing both skeletal muscle and cardiac fibrosis compared
to naproxen, with less gastro-intestinal side effects. In
addition, naproxcinod could be the most appropriate
CINOD for pediatric application considering that na-
proxen is approved for children and that drugs impacting
on the pathway of NO such as tadalafil are currently under
development for DMD patients.
Moreover, these data suggest that NO is responsible
for the additional beneficial effects of naproxcinod over
naproxen, suggesting a key role of NO donation in
slowing disease progression in the mdx mouse model.
Our findings conclusively indicate that naproxcinod
has significant potential as a safe therapeutic option for
the treatment of DMD.
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